Table 1 Patient characteristics

Age

69.3 ± 8.1

PSA (ng/mL)

261 (IQR: 92.5–618)

Gleason score

 8 or higher

60 (85%)

T stage

 1

1 (1%)

 2

26 (37%)

 3

24 (34%)

 4

17 (24%)

 Unknown

3 (4%)

N stage

 0

28 (39%)

 1

43 (61%)

M stage

 Bone

65 (92%)

 Visceral

17 (24%)

mCRPC

57 (80%)

Serum testosterone values (ng/dL)

12 (IQR: 6–21)

EOD score of 2 or more

38 (57%)

CAB therapy

69 (97%)

Used BMA

34 (48%)

Median PSA levels after 3 months of ADT

2.6 (0.03–1092)

Median PSA levels after 3 months of ADT (%)

1.1 (0.01–103.7)

Median observation periods (months)

38 (5–156)